Primary Outcome Measures:
- Number of Adverse Events [ Time Frame: 3 ] [ Designated as safety issue: Yes ]
Abstract Brief abstract (250 words or less) describing the study in language understandable to a lay person. Include brief description of the purpose, target disease/condition if applicable, key eligibility criteria, and main study interventions This is a Phase II investigator-Initiated trial of the Investigational Drug, Ruxolitinib, in combination with Exemestane in patients with estrogen-receptor positive advanced breast cancer. The objective of this study is to determine the preliminary safety and efficacy of the combination of exemestane and Ruxolitinib (INCB018424). A maximum of 25 people will be enrolled on this study at the University of Pennsylvania.
As part of this study, subjects have the option of providing separate consent for research related biopsies (at baseline and Cycle 1/Day 22). If they provide consent, subjects will be co-enrolled on a separate sample acquisition research study under the direction of Dr. Angela DeMichele (IRB #811841/UPCC#17110: Collection of Tumor Tissue, Blood and Clinical Data from Patients with Advanced Breast Cancer (short name TRACR-MET)) through which these biopsies will be performed with Radiology support. The study team will review this separate consent with the study subjects considering participation in this optional component so that they can make a fully educated decision regarding whether or not they would like to participate.